Clinical efficacy and safety of sodium glucose cotransporter 2 inhibitors - experience in a regional hospital

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: TSENG, Hsiang-Yi (Tungs’ Taichung MetroHarbor Hospital, Department of Pharmacy, Taichung, China Taiwan)
  • Co-author(s): Hsiang-Yi Tseng: Department of Pharmacy, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan, Province of China;, Taichung City New Pharmacist Association, Taichung, Taiwan, Province of China
    Wen-Cheng Hsu: Department of Endocrinology and Metabolism, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan, Province of China
    Hui-Chun Tsai: Diabetes Mellitus Education Room, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan, Province of China
    Pei-Liang Chen: Department of Pharmacy, Tungs’ Taichung MetroHarbor Hospital, Taichung, Taiwan, Province of China;, Taichung City New Pharmacist Association, Taichung, Taiwan, Province of China
  • Abstract:

    Background

    Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients study demonstrated empagliflozin reduced the major cardiac events in T2DM patients with high CVD risk and was associated with slower progression of kidney disease.

    Purpose

    Evaluate efficacy and safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i), ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login